SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Open-market buys and sells only — the deliberate trades. Zero here doesn’t mean no filings: grants, option exercises and tax withholding (below) are compensation, not market trades.
| Insider | Role | Date | Transaction | Shares | Value |
|---|---|---|---|---|---|
| Foster Julie | President, Front Line Care | 2026-09-02 | Tax withholding | 2098 | $54K |
| Hider Andrew P. | President and CEO, Director | 2026-09-02 | Tax withholding | 54276 | $1.4M |
| Teaff James | President, CCS | 2026-09-01 | Tax withholding | 750 | $19K |
| Teaff James | President, CCS | 2026-06-02 | Tax withholding | 321 | $6K |
| Wallace Steven P. | President, Adv. Surgery | 2026-06-02 | Tax withholding | 153 | $3K |
| Zielinski Anita A | SVP, Interim CFO, CAO & Cntrlr | 2026-06-01 | Grant/award | 13426 | $0 |
| Ampofo William A. II | Director | 2026-05-05 | Grant/award | 12836 | $0 |
| Craig Jeffrey A | Director | 2026-05-05 | Grant/award | 12836 | $0 |
| MORRISON PATRICIA | Director | 2026-05-05 | Grant/award | 12836 | $0 |
| McDonnell Michael R. | Director | 2026-05-05 | Grant/award | 12836 | $0 |
| SCHLICHTING NANCY M | Director | 2026-05-05 | Grant/award | 12836 | $0 |
| Shafer David Brent | Director | 2026-05-05 | Grant/award | 12836 | $0 |
| Wendell Amy McBride | Director | 2026-05-05 | Grant/award | 12836 | $0 |
| Wilkes David S. | Director | 2026-05-05 | Grant/award | 12836 | $0 |
| Grade Joel T. | EVP and CFO | 2026-03-06 | Tax withholding | 8153 | $144K |
| Rasul Reazur | EVP,Group Pres,Healthcare | 2026-03-06 | Tax withholding | 12674 | $224K |
| Rosenbloom David S. | EVP and General Counsel | 2026-03-06 | Tax withholding | 6620 | $117K |
| Soriano Maria Cecilia | Group Pres., ITT & Pharma. | 2026-03-06 | Tax withholding | 2848 | $50K |
| Zielinski Anita A | SVP, CAO and Controller | 2026-03-06 | Tax withholding | 1932 | $34K |
| Rasul Reazur | EVP,Group Pres,Healthcare | 2026-03-02 | Tax withholding | 1614 | $32K |
Fiscal period ending 2025-12-31 versus 2024-12-31 — view filing on EDGAR →
Baxter's risk profile has deteriorated broadly and materially, with worsening spanning six distinct themes — operations/supply chain, regulatory/compliance, debt/capital structure, restructuring, technology, and governance — driven by concrete, realized disruptions rather than hypothetical exposures. The partial debt reduction from the Kidney Care sale is offset by new leverage constraints on R&D, a dividend cut to $0.01/share, an explicit 2026 net leverage deadline, and downgrade risk, while simultaneous supply chain failures (Novum LVP ship hold, Hurricane Helene demand reset, manufacturing footprint reduction) and a cascade of new regulatory headwinds (Section 232 tariff investigation, CMS Competitive Bidding expansion, reimbursement policy risk) compound the operational stress. A new CEO transition, Hillrom integration delays, and AI/cybersecurity governance gaps add execution and control risk at a moment when the company has little margin for error.
16 company-specific · 3 eased/removed · 6 common-mode
New disclosure of material supply chain disruptions causing production delays, cost increases, inventory buildup, and lost sales. Concrete operational and financial impact.
We have experienced disruptions in our supply chain . We have experienced significant challenges to our global supply chain in recent periods, including: • production delays and interruptions; •…
New disclosure of material competitive and pricing pressures from healthcare consolidation, government tenders favoring domestic suppliers, and regulatory bias against multinationals like Baxter.
Continued consolidation in the health care industry or additional governmental controls exerted over pricing and access in key markets could lead to increased demands for price concessions or limit…
Kidney Care sale now complete (January 2025) with confirmed debt repayment and interest savings. New disclosure of Hillrom integration delays and additional expenses. Shift from prospective to realized transaction risks.
We may not achieve the anticipated benefits of our significant transactions, including the sale of our Kidney Care business and our acquisition of Hillrom. We have undertaken several significant…
Added specific operational impacts: Hurricane Helene demand reset in IV solutions, elevated inventory levels, and harder demand forecasting. Concrete business consequences now disclosed.
There is substantial competition in the product markets in which we operate and the risk of declining demand and pricing pressures could adversely affect our business, results of operations…
New disclosure that leverage constrains R&D funding ability, linking debt burden to product development capacity—a material operational constraint.
We may be unable to successfully introduce or monetize new and existing products or services or keep pace with changing consumer preferences and needs or advances in technology. We need to…
New disclosure of ongoing Novum LVP voluntary corrections and ship hold in 2025 escalates quality risk from hypothetical to concrete operational impact with financial consequences.
We have experienced and may continue to experience issues with quality management or product quality. The development of new or enhanced products involves a lengthy regulatory process and is capital…
New disclosure of Section 232 investigation into pharmaceutical/medical device imports for national security purposes, with potential tariff implications. Specific regulatory action escalates prior generic trade tension language.
We are subject to risks associated with doing business globally. Our operations are subject to risks inherent in conducting business globally and under the laws, regulations and customs of various…
Dividend cut to $0.01/share announced November 2025 signals financial stress and deleveraging priority. Material to equity investors and credit analysis.
Risks Relating to Our Common Stock We recently decreased our quarterly dividend to $0.01 per share and cannot guarantee that we will increase the amount of dividends we pay, or that we will not cease…
New explicit disclosure of quality management and product quality issues. Prior year omitted this risk; current year elevates it as standalone factor.
Risks Relating to Our Operations • Segments of our business are significantly dependent on major contracts with GPOs, IDNs, and certain other distributors and purchasers. • We may be unable to…
Added explicit dependencies on restructuring savings, new product innovation, manufacturing footprint optimization, and external factors (competition, regulation). Escalated language from "material" to "significant" adverse effect.
We may not achieve our financial goals. We continue to evaluate and refine both our short- and long-term financial objectives, including our stated commitment to achieve certain net leverage targets…
Expanded scope: now includes manufacturing footprint simplification and explicit linkage to net leverage and cash flow targets, signaling broader, more aggressive restructuring ahead.
We may not be successful in achieving expected operating efficiencies and sustaining or improving operating expense reductions and may experience business disruptions and adverse tax consequences…
New disclosure of federal workforce freeze/reduction delays in FDA approval of materials and components, creating operational risk not previously disclosed.
We may be unable to obtain sufficient components or raw materials on a timely basis or for a cost-effective price. The manufacture of our products requires, among other things, the timely supply or…
New disclosure of ongoing manufacturing footprint reduction restructuring impacting supply chain and product availability. Adds concrete operational risk beyond prior generic supply chain language.
We may experience manufacturing, sterilization, supply, or distribution difficulties. As of December 31, 2025, we manufacture our products at various facilities globally. Many of our products are…
Company now explicitly states tariffs have adversely affected results and expects continued negative impact. Removes specific Mexico tariff example, broadens tariff risk language, and adds quantified impact disclosure.
Risks Relating to Legal and Regulatory Matters We are subject to laws and regulations globally, and our failure to comply with rapidly changing and increasingly divergent expectations of regulators…
New disclosure of tax indemnification obligations from strategic divestitures adds material contingent liability exposure not previously disclosed.
We may incur additional tax expense or become subject to additional tax liabilities. Changes to the tax laws in the U.S. or other countries in which we operate, such as the evolving two-pillared plan…
New CEO transition risk and product quality/release delays disclosed. CEO change and operational execution risks are material to investors.
Our common stock price has fluctuated significantly and may continue to do so in the future. The price of our common stock has fluctuated significantly and may continue to do so in the future for a…
Debt reduced from $13.13B to $9.48B (28% decrease). However, new risks emerged: pension funding obligations, dividend cut, specific 2026 net leverage target deadline, and explicit investment-grade rating downgrade risk.
Our significant indebtedness requires us to use a substantial amount of our cash flow for debt service and constrains our ability to pursue growth strategies and advance our R&D capabilities. As of…
Prior year detailed extensive Kidney Care sale execution risks; current year consolidates into brief bullet points. Substantive de-emphasis of transaction-specific operational and dispute risks.
Risks Relating to Our Business and Financial Performance • We are exposed to risks as a result of our strategic actions. • We may not achieve the anticipated benefits of our significant…
Kidney Care sale risks substantially reduced post-closing. Transition services, supply agreements, and specific pre-closing liabilities no longer disclosed as active concerns. Risk reframed as historical rather than ongoing.
Risks Relating to Our Business and Financial Performance We are exposed to risks as a result of our strategic actions. Our businesses have faced, and will continue to face, challenges in connection…
New disclosure of reimbursement risk from government healthcare policy changes. Material for healthcare/pharma companies as pricing/reimbursement directly impacts revenue and profitability.
If reimbursement or other payment for our current or future products is reduced or modified in the U.S. or in foreign countries, including through the implementation or repeal of government-sponsored…
New disclosure of CMS Competitive Bidding Program expansion risk with specific device categories and potential adverse pricing/demand effects.
reform or other similar actions, cost containment measures, or there are changes to policies with respect to pricing, taxation, or rebates, our business could suffer. Sales of our products depend, in…
New explicit disclosure of adversarial AI risks impacting detection and containment; removal of regulatory compliance assurance language; simplified but more direct risk framing.
We may experience breaches and breakdowns affecting our information technology systems or protected information, including from obsolescence, cyber security breaches and data leakage. We rely upon…
New disclosure of internal AI governance policy ineffectiveness risk and AI-specific cybersecurity risks. Adds data leakage risk and regulatory action exposure not previously emphasized.
We are exposed to risks associated with incorporating AI, machine learning and other emerging technologies into our products, services and operations. We use both internally developed and third…
Risk escalated: added "loss of sales" as realized impact, expanded regulatory scope to "sustainability topics," introduced litigation/fines risk, and emphasized supplier compliance uncertainty.
The effects of climate change, including legal, regulatory, or market measures related to climate change and other sustainability topics, could adversely affect our business, results of operations…
Added explicit consequences: regulatory fines, business disruption, reputational harm, financial loss, litigation. New disclosure of competitive/marketability risk from cybersecurity standards.
Increasing regulatory focus on, and expanding laws relating to, privacy, AI, and cybersecurity could impact our business and expose us to increased liability. As a global company, we are subject to…
Baxter International appointed John Rogers as Executive Vice President and Chief Financial Officer, effective October 1, 2026. Rogers' compensation package includes a base salary of $925,000, target bonus of 100% of base, equity grants totaling $4,000,000 LTI target value, and a sign-on bonus of $2,827,629.
View raw filing on EDGAR →Anita Zielinski's resignation as Interim Chief Financial Officer and Senior Vice President, Chief Accounting Officer and Controller, effective September 15, 2026, is a departure of a senior executive officer. The CFO role is material to investors' assessment of financial oversight and governance. Although the filing explicitly states no disagreement with management or the board, the departure itself is a material event requiring disclosure under Item 5.02.
View raw filing on EDGAR →Baxter announced cash tender offers to repurchase up to $500 million in aggregate principal amount of outstanding senior notes across four series (due 2051, 2046, 2043, and 2032). While this is technically a debt repurchase rather than new debt issuance, it represents a material capital structure transaction that creates or modifies direct financial obligations. The $500 million cap, multiple series involved, and detailed terms (early tender premiums, acceptance priority levels, settlement dates) indicate a significant financial event affecting the company's debt portfolio and liquidity position.
View raw filing on EDGAR →Baxter International issued an earnings press release for Q2 2026 (period ended June 30, 2026) disclosing sales of $2.96 billion (5% growth), U.S. GAAP diluted EPS of $0.26, adjusted diluted EPS of $0.56, and raising full-year 2026 guidance for reported sales growth (3-4%), organic sales growth (2-3%), and adjusted EPS ($1.95-$2.15).
View raw filing on EDGAR →Baxter disclosed a material reorganization of its reportable segments effective Q2 2026, consolidating from three segments (Medical Products & Therapies, Healthcare Systems & Technologies, Pharmaceuticals) to two (MPT and HST), with the former Pharmaceuticals segment now nested within MPT's Infusion Therapies & Platforms division. The company also updated corporate cost allocation methodology. While the filing explicitly states this does not constitute a restatement and does not affect consolidated net income, EPS, total assets, or stockholders' equity, the segment restructuring reflects a fundamental change in how the chief operating decision maker allocates resources and assesses performance—a material operational and strategic realignment that would affect investor analysis of business performance and comparability across periods.
View raw filing on EDGAR →